{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:09:10Z","timestamp":1772885350920,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>This study aimed to evaluate the role of various metabolic parameters derived from baseline <jats:sup>18<\/jats:sup>F-FDG PET\/CT in predicting the prognosis of stage IV non\u2013small cell lung cancer (NSCLC) patients scheduled to receive osimertinib treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>A retrospective analysis was conducted on 177 NSCLC patients (98 males, 79 females; mean age 58.5 \u00b1 11.0\u00a0y) who underwent osimertinib therapy and <jats:sup>18<\/jats:sup>F-FDG PET\/CT scanning before treatment. Clinical and PET\/CT parameters were assessed, including age, sex, smoking history, brain metastasis, bone metastasis, CEA level, SUVmax, SUVmean, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Receiver operating characteristic (ROC) curve analysis was used to calculate the optimal cutoff values for all parameters. Progression-free survival (PFS) was analyzed using log-rank tests, Kaplan-Meier curves, and Cox proportional hazard models to identify prognostic markers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean follow-up period was 15.24 \u00b1 8.14 months. Univariate analysis revealed that SUVmax, SUVmean, MTV, and TLG were significantly associated with PFS, with cutoff values of 12.3, 8.57, 13.49 cm<jats:sup>3<\/jats:sup>, and 162.37, respectively. The hazard ratios were 1.776 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.007), 2.155 (<jats:italic toggle=\"yes\">P<\/jats:italic>\uff1c0.001), 3.312 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), and 3.370 (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), respectively. Multivariate survival analysis indicated that MTV was an independent prognostic factor for PFS (HR = 2.323; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.012).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Baseline PET\/CT metabolic parameters before osimertinib treatment may help identify potential NSCLC patients who could derive clinical benefit, and baseline MTV of the primary tumor from <jats:sup>18<\/jats:sup>F-FDG PET\/CT is a reliable prognostic indicator for PFS in stage IV NSCLC patients treated with osimertinib.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006039","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T22:00:31Z","timestamp":1752530431000},"page":"e516-e522","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Prognostic Value of Baseline 18F-FDG PET\/CT in Stage IV Non\u2013Small Cell Lung Cancer Patients Receiving Osimertinib Treatment"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2812-0536","authenticated-orcid":false,"given":"Zhen-peng","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Guangzhou First People\u2019s Hospital, School of Medicine, South China University of Technology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-min","family":"Shan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Guangzhou First People\u2019s Hospital, School of Medicine, South China University of Technology"},{"name":"Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of PET Center, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of PET Center, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-yu","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of PET Center, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of PET Center, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"R1-20250731","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1038\/s41467-021-22971-x","article-title":"An RFC4\/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12916-021-02118-x","article-title":"Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC","volume":"19","author":"Zhang","year":"2021","journal-title":"BMC Med"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1038\/s41467-020-18442-4","article-title":"Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.3390\/ijms23136936","article-title":"Acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer: how do we overcome it?","volume":"23","author":"Bertoli","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.neo.2021.05.006","article-title":"Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma","volume":"23","author":"Li","year":"2021","journal-title":"Neoplasia"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1148\/radiol.12111148","article-title":"Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET\/CT in non-small cell lung cancer","volume":"264","author":"Chen","year":"2012","journal-title":"Radiology"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.lungcan.2020.09.020","article-title":"Value of interim 18F-FDG PET\/CT for predicting progression-free survival in stage IIIB\/IV EGFR-mutant non\u2013small-cell lung cancer patients with EGFR-TKI therapy","volume":"149","author":"Shao","year":"2020","journal-title":"Lung Cancer"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/RLU.0000000000001886","article-title":"Role of various metabolic parameters derived from baseline 18F-FDG PET\/CT as prognostic markers in non\u2013small cell lung cancer patients undergoing platinum-based chemotherapy","volume":"43","author":"Sharma","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"1014063","DOI":"10.3389\/fimmu.2022.1014063","article-title":"Prognostic value of 18F-FDG PET\/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Ling","year":"2022","journal-title":"Front Immunol"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3390\/cancers12051163","article-title":"18F-FDG PET parameters and radiomics features analysis in advanced NSCLC treated with immunotherapy as predictors of therapy response and survival","volume":"12","author":"Polverari","year":"2020","journal-title":"Cancers"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"47","author":"Seban","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20250731","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13014-023-02224-5","article-title":"Prognostic value of baseline 18F-FDG PET\/CT in patients with esophageal squamous cell carcinoma treated with definitive (chemo)radiotherapy","volume":"18","author":"Xia","year":"2023","journal-title":"Radiat Oncol"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"652312","DOI":"10.3389\/fonc.2021.652312","article-title":"Prognostic significance of SUVmax combined with lactate dehydrogenase in advanced lung cancer patients treated with immune checkpoint inhibitor plus chemotherapy: a retrospective study","volume":"11","author":"Ke","year":"2021","journal-title":"Front Oncol"},{"key":"R16-20250731","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40644-022-00513-y","article-title":"Whole body FDG PET\/MR for progression free and overall survival prediction in patients with relapsed\/refractory large B-cell lymphomas undergoing CAR T-cell therapy","volume":"22","author":"Sj\u00f6holm","year":"2022","journal-title":"Cancer Imaging"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.acra.2011.08.020","article-title":"Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET\/CT in stage IV nonsurgical small-cell lung cancer","volume":"19","author":"Liao","year":"2012","journal-title":"Acad Radiol"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00432-013-1545-7","article-title":"FDG PET\/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma","volume":"140","author":"Chung","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2023.02.011","article-title":"Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): a multicenter, single-arm, open-label phase 2b trial","volume":"178","author":"Lv","year":"2023","journal-title":"Lung Cancer"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"R21-20250731","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.03.020","article-title":"Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-small cell lung cancer treated with first-line pembrolizumab","volume":"150","author":"Dall\u2019Olio","year":"2021","journal-title":"Eur J Cancer"},{"key":"R22-20250731","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.semnuclmed.2022.04.007","article-title":"The value of the standardized uptake value (SUV) and metabolic tumor volume (MTV) in lung cancer","volume":"52","author":"Hicks","year":"2022","journal-title":"Semin Nucl Med"},{"key":"R23-20250731","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00259-016-3577-0","article-title":"Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib","volume":"44","author":"Lim","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-20250731","first-page":"615","article-title":"Prognostic value of metabolic tumor burden in lung cancer","volume":"25","author":"Obara","year":"2013","journal-title":"Chin J Cancer Res"},{"key":"R25-20250731","doi-asserted-by":"crossref","first-page":"111198","DOI":"10.1016\/j.ejrad.2023.111198","article-title":"Metabolic tumor volume and sites of organ involvement predict outcome in NSCLC immune-checkpoint inhibitor therapy","volume":"170","author":"Kifjak","year":"2024","journal-title":"Eur J Radiol"},{"key":"R26-20250731","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/RLU.0000000000001126","article-title":"Prognostic value of volumetric parameters on staging and posttreatment FDG PET\/CT in patients with stage IV non\u2013small cell lung cancer","volume":"41","author":"Lee","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R27-20250731","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s13139-012-0165-5","article-title":"Metabolic tumor volume measured by F-18 FDG PET\/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer","volume":"46","author":"Yoo","year":"2012","journal-title":"Nucl Med Mol Imaging"},{"key":"R28-20250731","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1097\/JTO.0b013e3181a97df7","article-title":"Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer","volume":"4","author":"Dooms","year":"2009","journal-title":"J Thorac Oncol"},{"key":"R29-20250731","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1200\/JCO.2012.47.5947","article-title":"Prediction of survival by [18F]Fluorodeoxyglucose positron emission tomography in patients with locally advanced non\u2013small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668\/RTOG 0235 trial","volume":"31","author":"Machtay","year":"2013","journal-title":"J Clin Oncol"},{"key":"R30-20250731","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"R31-20250731","doi-asserted-by":"crossref","first-page":"780186","DOI":"10.3389\/fonc.2022.780186","article-title":"A review of the correlation between epidermal growth factor receptor mutation status and 18F-FDG metabolic activity in non-small cell lung cancer","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"R32-20250731","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"R33-20250731","doi-asserted-by":"crossref","first-page":"e0189766","DOI":"10.1371\/journal.pone.0189766","article-title":"Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor","volume":"13","author":"Park","year":"2018","journal-title":"PLoS One"},{"key":"R34-20250731","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00259-011-1934-6","article-title":"Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer","volume":"39","author":"Liao","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:00:40Z","timestamp":1753938040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006039","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"2024-11-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}